Boston Scientific (NYSE:BSX) Director Acquires 2,100 Shares of Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger purchased 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Boston Scientific Price Performance

Boston Scientific stock traded up $0.05 during trading hours on Friday, reaching $49.35. 11,443,129 shares of the stock were exchanged, compared to its average volume of 18,379,627. The company has a current ratio of 1.24, a quick ratio of 1.22 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a market cap of $71.53 billion, a P/E ratio of 19.98, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The stock has a 50 day moving average of $45.73 and a two-hundred day moving average of $60.81.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the company earned $0.75 EPS. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

BSX has been the subject of several recent analyst reports. Bank of America cut their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Raymond James Financial reiterated an “outperform” rating and issued a $57.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Barclays lowered their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Weiss Ratings downgraded Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Finally, Jefferies Financial Group reduced their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $71.62.

Institutional Trading of Boston Scientific

Several hedge funds and other institutional investors have recently made changes to their positions in BSX. BlackRock Inc. bought a new position in shares of Boston Scientific during the second quarter valued at $5,534,781,000. Norges Bank acquired a new position in shares of Boston Scientific during the fourth quarter worth $2,199,395,000. Bank of New York Mellon Corp bought a new stake in shares of Boston Scientific in the second quarter worth $339,031,000. Deutsche Bank AG bought a new stake in shares of Boston Scientific in the second quarter worth $254,247,000. Finally, Assenagon Asset Management S.A. increased its holdings in Boston Scientific by 133.6% in the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock valued at $631,135,000 after purchasing an additional 5,751,760 shares during the period. 89.07% of the stock is currently owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.